Float Short %

13.81

Margin Of Safety %

-22

Put/Call OI Ratio

0.18

EPS Next Q Diff

0.08

EPS Last/This Y

-6.34

EPS This/Next Y

3.44

Price

82.83

Target Price

101.08

Analyst Recom

1.23

Performance Q

-1.93

Upside

-73.4%

Beta

2.25

Ticker: PTGX

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-23	PTGX	83.17	0.10	1.00	6782
2026-01-26	PTGX	82.18	0.10	0.00	6790
2026-01-27	PTGX	83.09	0.10	0.14	6814
2026-01-28	PTGX	81.78	0.10	10.59	6854
2026-01-29	PTGX	79.61	0.19	0.29	7418
2026-01-30	PTGX	81.84	0.19	0.16	7566
2026-02-02	PTGX	83.07	0.19	0.06	7540
2026-02-03	PTGX	85.58	0.20	0.00	7479
2026-02-04	PTGX	83.39	0.20	2.03	7483
2026-02-05	PTGX	80.68	0.19	0.80	7452
2026-02-06	PTGX	84.4	0.19	0.00	7448
2026-02-09	PTGX	83.32	0.19	3.57	7447
2026-02-10	PTGX	83.87	0.19	0.00	7461
2026-02-11	PTGX	83.43	0.19	0.05	7461
2026-02-12	PTGX	81.88	0.19	0.83	7452
2026-02-13	PTGX	81.5	0.19	0.00	7453
2026-02-17	PTGX	82.46	0.19	0.01	7459
2026-02-18	PTGX	82.82	0.19	0.00	7463
2026-02-20	PTGX	82.84	0.18	0.21	7833
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-23	PTGX	83.12	-128.3	-	-1.87
2026-01-26	PTGX	82.18	-128.3	-	-1.87
2026-01-27	PTGX	83.11	-128.3	-	-1.87
2026-01-28	PTGX	81.82	-128.3	-	-1.87
2026-01-29	PTGX	79.71	-128.3	-	-1.87
2026-01-30	PTGX	81.81	-128.3	-	-1.87
2026-02-02	PTGX	83.11	-128.3	-	-1.87
2026-02-03	PTGX	85.52	-127.3	-	-1.87
2026-02-04	PTGX	83.32	-127.3	-	-1.87
2026-02-05	PTGX	80.71	-127.3	-	-1.87
2026-02-06	PTGX	84.47	-127.3	-	-1.87
2026-02-09	PTGX	83.20	-127.3	-	-1.87
2026-02-10	PTGX	83.87	-127.3	-	-1.87
2026-02-11	PTGX	83.44	-127.3	-	-1.87
2026-02-12	PTGX	81.89	-127.3	-	-1.87
2026-02-13	PTGX	81.48	-127.3	-	-1.87
2026-02-17	PTGX	82.38	-127.3	-	-1.87
2026-02-18	PTGX	83.00	-127.3	-	-1.87
2026-02-19	PTGX	82.96	-127.3	-	-1.87
2026-02-20	PTGX	82.83	-127.3	-	-1.87
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-23	PTGX	-3.68	-0.44	12.38
2026-01-26	PTGX	-2.32	-0.49	12.37
2026-01-27	PTGX	-2.35	-0.49	12.37
2026-01-28	PTGX	-5.41	-0.49	14.07
2026-01-29	PTGX	-5.14	-0.49	14.07
2026-01-30	PTGX	-5.14	-0.49	14.07
2026-02-02	PTGX	-5.14	-0.54	14.07
2026-02-03	PTGX	-5.20	-0.54	14.07
2026-02-04	PTGX	-5.20	-0.54	14.07
2026-02-05	PTGX	-5.20	-0.54	14.07
2026-02-06	PTGX	-5.70	-0.54	14.07
2026-02-10	PTGX	-5.70	4.22	14.07
2026-02-11	PTGX	-5.70	4.22	13.79
2026-02-12	PTGX	-5.70	4.22	13.79
2026-02-13	PTGX	-5.70	4.22	13.79
2026-02-17	PTGX	-5.70	10.32	13.79
2026-02-18	PTGX	-6.16	10.32	13.79
2026-02-19	PTGX	-6.16	10.32	13.79
2026-02-20	PTGX	-6.16	10.32	13.81
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.62

Avg. EPS Est. Current Quarter

-0.56

Avg. EPS Est. Next Quarter

-0.54

Insider Transactions

-6.16

Institutional Transactions

10.32

Beta

2.25

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

64.73

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

14.2

Max Drawdown 5-Year %

-85.8

Target Price

101.08

P/E

130.66

Forward P/E

56.84

PEG

P/S

24.73

P/B

8.01

P/Free Cash Flow

81.21

EPS

0.63

Average EPS Est. Cur. Y

-1.87

EPS Next Y. (Est.)

1.57

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

21.94

Relative Volume

0.7

Return on Equity vs Sector %

-21.9

Return on Equity vs Industry %

-4.4

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Protagonist Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 128

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

stock quote shares PTGX – Protagonist Therapeutics Inc Stock Price stock today

news today PTGX – Protagonist Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch PTGX – Protagonist Therapeutics Inc yahoo finance google finance

stock history PTGX – Protagonist Therapeutics Inc invest stock market

stock prices PTGX premarket after hours

ticker PTGX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: PTGX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y